The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a rare lung disease and the mammalian target of the rapamycin (mTOR) inhibitors has been used as an effective therapy. Here we conducted a systematic review and meta-analysis with the aims to quantify the efficacy and safety of mTOR inhibitors in LAM pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Nannan, Zhang, Tengyue, Ji, Jiadong, Xu, Kai-Feng, Tian, Xinlun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092843/
https://www.ncbi.nlm.nih.gov/pubmed/30107845
http://dx.doi.org/10.1186/s13023-018-0874-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092843/
https://www.ncbi.nlm.nih.gov/pubmed/30107845
http://dx.doi.org/10.1186/s13023-018-0874-7

Ejemplares similares